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Abstract
Background: Hypertensive crisis is a medical emergency that can cause acute damage to multiple end-organs.
However, relatively little is known on the etiology, treatment, and outcomes of hypertensive crisis in Korean
children. The aim of this study was to determine the etiologies and efficacy of drugs for hypertensive crisis in
children during the past 5 years at a single center in Korea.
Methods: We analyzed data from 51 children with hypertensive crisis during the period between January 1, 2010
and April 1, 2014. The patients were divided into two groups: those diagnosed with a hypertensive emergency
(hypertension with organ injury, n = 31) and those diagnosed with a hypertensive urgency (hypertension without
organ injury, n = 20). Baseline etiologies and risk factors were compared between the two groups. In addition,
systolic and diastolic blood pressures were evaluated at 1, 2, 4, and 5 hours after the administration of intravenous
antihypertensive drugs.
Results: Kidney injury and cancer were the common causes in patients with hypertensive crisis. Cardiovascular
complications (cardiac hypertrophy) (p = 0.002), central nervous system complications (p = 0.004), and
retinopathy (p = 0.034) were more frequently observed in children with hypertensive emergency than those with
hypertensive urgency. However, the proportion of renal complications was similar in both groups. Hydralazine was
most commonly used in both groups to control acute increasing blood pressure at first. However, it was often
ineffective for controlling abrupt elevated blood pressure. Therefore, intravenous antihypertensive drugs were changed
from hydralazine to nicardipine, labetalol, or nitroprusside to control the high blood pressure in 45.1 % of the patients.
Particularly, in patients with hypertensive crisis, there was no significant difference in reduction of systolic and diastolic
blood pressure and in improvement of clinical outcomes between nicardipine and labetalol administration.
Conclusion: Close blood pressure monitoring and careful examinations should be mandatory in children with
underlying disease, especially renal diseases and cancer. Furthermore, both nicardipine and labetalol may be effective
antihypertensive drug in lowering high blood pressure in children with hypertensive crisis.
Keywords: Hypertensive crisis, Antihypertensive drugs, Children
Background
Hypertension in children is defined as a sustained sys-
tolic blood pressure (SBP) or diastolic blood pressure
(DBP) elevation status greater than or equal to the 95th
percentile for age, gender, and height [1]. Several studies
including National Health and Nutrition Examination
Survey (NHANES) have shown that the morbidity of
hypertension in children and adolescents is about 1-4 %,
and the average blood pressure is recently increasing
during childhood [1–3].
Hypertensive crisis is a clinical syndrome of severe
hypertension that can cause life-threatening status [4–6].
This term can be subdivided into two groups: a
“hypertensive emergency,” which has signs of organ
failure, and a “hypertensive urgency,” which does not
have any other complication except elevation of blood
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pressure [7–11]. Approximately 20 % to 40 % of
hypertensive crises are hypertensive emergencies, and
60 % to 80 % are hypertensive urgencies [11, 12]. Hyper-
tensive emergency can lead to multiorgan damage, requir-
ing urgent management to reduce blood pressure [4–6].
The organs susceptible to impairment include the brain,
eyes, heart, and kidneys, with the major pathological
process being fibroid necrosis of arterioles [6].
Hypertensive crisis, however, is rare in children, and
the prevalence of hypertensive crisis in children is
currently unknown [13]. In addition, studies on the
choice for the initial antihypertensive drugs are still
lacking. The aim of this study was to determine the
etiologies and efficacy of drugs for hypertensive crisis
in children.
Methods
The medical records were retrospectively reviewed to
search for patients with hypertensive crisis admitted to
Yonsei University Severance Hospital during the study
period (January 1, 2010 to April 1, 2014). The inclusion
criteria for patients were as follows: 1) below 20 years of
age; 2) diagnosis of hypertensive crisis which has
symptoms and significant elevations in blood pressure
with or without accompanying end-organ damage; and
3) treated with intravenous hydralazine or continuous
nicardipine, labetalol, and nitroprusside infusion. Partici-
pants were excluded if they had an immediately-
postoperative status. Therefore, we enrolled a total num-
ber of 51 patients.
The patients with hypertensive crisis were divided into
two groups according to the presence of end-organ dam-
age: hypertensive emergency (organ injury, n = 31) and
hypertensive urgency (no organ injury, n = 20). The def-
inition of end-organ damage was having signs or symp-
toms suggesting a hypertensive emergency such as visual
symptoms, seizure, anuria, hematuria, or abnormal find-
ings in a 12-lead electrocardiogram or echocardiography.
Data collected included age, sex, and etiology of hyper-
tension. Additionally, serum blood urea nitrogen (BUN)
and creatinine (Cr) were collected as laboratory data.
SBP and DBP were measured hourly after continuous in-
fusion of antihypertensive agent. Baseline etiologies and
characteristics were also compared between the two
groups.
Baseline blood pressure was also assessed and was
defined as the patient's highest blood pressure before
starting the medication. Blood pressure was then mea-
sured every hour until 5 hours after initiation of the an-
tihypertensive medication.
For statistical analysis, continuous-value data for each
group were compared using a student t-test, and a chi
square test was used for categorical variables using SPSS
version 18.0 (SPSS Inc., Chicago, IL, USA). A p-value
of <0.05 was considered to have statistical significance.
This study was approved by the Institutional Review
Board (IRB) of Severance Hospital (Seoul, Korea, IRB No.
4-2015-0144).
Results
Baseline etiologies were presented in Table 1. Cancer
was the most common cause (47.0 %) of hypertensive
crisis in children. Most of cancer patients showed hyper-
tensive crisis after receiving chemotherapy such as cyclo-
phosphamide, cisplatin and methotrexate, known as
nephrotoxic agents. Only 3 cases of Wilms’ tumor
showed hypertensive crisis by cancer mass itself. Kidney
injury was the second common cause (29.5 %), which
contained three subtype etiologies: renal disease (15.7 %
of the patients), post-renal disease (6.0 %), and renal
artery stenosis (7.8 %). Particularly, patients with renal
diseases consisted of acute poststreptococcal glomerulo-
nephritis (APSGN), thrombotic microangiopathy (TMA),
and drug-induced tubulointerstitial nephritis (TIN). Base-
line characteristics were similar between the two groups
with respect to age, sex, and etiologies. Only hypoxic brain
injury patients were higher in the hypertensive ur-
gency group than in the hypertensive emergency group
(p = 0.029) (Table 2).
Table 1 Etiologies of the patients who were treated for
hypertensive crisis
Etiology Number of patients Percentage (%)
Kidney origin 15 29.5
Renal disease 8 15.7
APSGN 3 6.0
Nephrotic syndrome 2 3.9
TMA 2 3.9
Drug-induced TIN 1 2.0
Postrenal disease 3 6.0
Reflux nephropathy 1 2.0
Ureter stricture 1 2.0
Post renal stone 1 2.0
Renal artery stenosis 4 7.8
Cancer 24 47.0
Wilms’ tumor 3 6.0
Neuroblastoma 2 3.9
Other solid tumor 7 13.7
Hematologic cancer 12 23.5
Sepsis 4 7.8
Hypoxic brain injury 6 11.8
Cardiogenic 2 3.9
Total 51 100
APSGN, acute poststreptococcal glomerulonephritis; TMA, thrombotic
microangiopathy; TIN, tubulointerstitial nephritis
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Systemic signs and symptoms suggestive of potential
end-organ damage were presented in Table 3. Hyperten-
sive emergencies caused the target organ damage to the
ophthalmologic, neurologic, cardiologic, and nephrologic
systems. Visual symptoms between the two groups did
not show the significant difference, but retinopathy was
more frequently observed in the hypertensive emergency
group than in urgency group (p = 0.034) on ophthalmo-
logic examination. Because two patients’ ophthalmologic
examination results were normal, they were classified as
hypertensive urgency group despite of having eye symp-
toms. In the hypertensive emergency group, 29.0 % of
the patients had seizures, and 62.5 % of the patients
were diagnosed with posterior reversible encephalopathy
syndrome (PRES), whereas no patients had either sign
(p = 0.004, p = 0.004, respectively) in the hypertensive ur-
gency group. Abnormal cardiovascular signs such as car-
diac hypertrophy were found in 43.3 % of the patients
on baseline 12-lead electrocardiogram and in 40.9 % of
the patients on echocardiogram in the hypertensive
emergency group, whereas no patient had such signs
in the hypertensive urgency group, with significant
differences (p = 0.002, p = 0.002, respectively). Kidney-
related symptoms and signs, including anuria, creatin-
ine elevation, BUN/Cr level, hematuria, and protein-
uria, did not show significant difference except for
renal ultrasonography, in which the hypertensive
emergency group showed more abnormal results (p =
0.025).
Treatment of the patients with hypertensive crisis in-
cluded hydralazine, nicardipine, and labetalol (Table 4).
Hydralazine was most commonly used to control acute
increasing blood pressure for the first time in 26 (51 %)
of the 51 patients. However, it was often ineffective for
controlling abrupt elevated blood pressure in 23 (88.5 %)
of the 26 patients. Therefore, the antihypertensive drug
was changed from hydralazine to nicardipine, labetalol,
or nitroprusside to control the high blood pressure in
the patients. Six labetalol infusions and three nitro-
prusside infusions were changed into nicardipine due
to poor blood pressure control. Only one patient
switched from nitroprusside to labetalol, and there
were no patients who were transferred from nicardi-
pine to other medications.
In both hypertensive emergency and hypertensive ur-
gency group, there was no significant difference in re-
duction of SBP and DBP between nicardipine and
labetalol administration (Table 5). However, nicardipine
showed more decreased SBP at 4 hours than labetalol,
although it had a borderline significance (Fig. 1).
We further evaluated the clinical outcomes after fin-
ishing treatment of intravenous nicardipine or labetalol
single infusion in both hypertensive emergency and ur-
gency patients (Table 6). Total 6 (26.0 %) patients even-
tually died and 17 (74.0 %) survived in nicardipine
group, otherwise 9 (50.0 %) patients died and 9 (50.0 %)
Table 2 Comparison of basal characteristics of the patients with
hypertensive emergency and urgency
Characteristics Hypertensive
emergency
(N = 31)
Hypertensive
urgency
(N = 20)
P value
Age (year) 8.46 ± 5.20 5.56 ± 4.71 0.051
Sex
Male (%) 18 (58.1) 10 (50.0)
0.572
Female (%) 13 (41.9) 10 (50.0)
Etiology
Renal origin (%) 10 (32.3) 5 (25.0) 0.951
Renal disease (%) 5 (16.1) 3 (15.0) 1.000
Postrenal disease (%) 2 (6.4) 1 (5.0) 1.000
Renal artery stenosis (%) 3 (9.8) 1 (5.0) 1.000
Cancer (%) 16 (51.7) 8 (40.0) 0.267
Sepsis (%) 2 (6.4) 2 (10.0) 0.640
Hypoxic brain injury (%) 1 (3.2) 5 (25.0) 0.029
Cardiogenic (%) 2 (6.4) 0 (0.0) 0.514
Table 3 Target organ damage of various organs in patients
with hypertensive crisis
Hypertensive
emergency
(N = 31)
Hypertensive
urgency
(N = 20)
P value
EYE
Visual symptom (%) 7 (22.6) 2 (10.0) 0.454
Retinopathy (%) 7/14 (50.0) 0/6 (0.0) 0.034
CNS
Seizure (%) 10 (29.0) 0 (0.0) 0.004
PRES on brain MRI (%) 10/16 (62.5) 0/11 (0.0) 0.004
HEART
LVH, RVH, BVH (%) 13/30 (43.3) 0/15 (0.0) 0.002
Abnormal EchoCG (%) 9/22 (40.9) 0/10 (0.0) 0.002
Ejection fraction 68.7 ± 9.70 68.1 ± 5.34 0.434
Kidney
Anuria (%) 14 (45.2) 8 (40.0) 0.778
Cr elevation (%) 15 (48.4) 9 (45.0) 1.000
BUN 27.07 ± 20.49 23.91 ± 19.80 0.294
Cr 1.08 ± 1.24 0.87 ± 1.13 0.278
Hematuria (%) 12 (38.7) 8 (40.0) 1.000
Proteinuria (%) 7 (22.6) 6 (30.0) 0.466
Abnormal renal USG (%) 10/20 (50.0) 0/8 (0.0) 0.025
CNS, central nervous system; PRES, posterior reversible encephalopathy
syndrome; LVH, Left ventricular hypertrophy; RVH, right ventricular
hypertrophy; BVH, biventricular hypertrophy; EchoCG, echocardiogram;
Cr, serum creatinine; BUN, blood urea nitrogen; USG, ultrasonography
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survived in labetalol infusion cases. Among these pa-
tients, we analyzed again only targeting survivors. In
nicardipine group, 10 (58.3 %) patients were taking oral
antihypertensive medications after intravenous treatment
and 7 (41.7 %) patients were tapered out all medications,
whereas 5 (55.6 %) patients were taking oral medica-
tions, 4 (44.4 %) patients were not taking any medica-
tions in labetalol group. Improvement of visual
symptoms, creatinine elevation, hematuria or protein-
uria, and abnormality on baseline 12-lead electrocardio-
gram did not show any significant difference between
the two groups.
Discussion
The main goal of this study was to investigate the causes
of pediatric hypertensive crisis and the efficacy of drugs
used to control it. We found that cancer and renal dis-
ease were the two common causes of hypertensive crisis
as described in other studies [14, 15]. Our study also ex-
hibited that there was no difference between nicardi-
pine and labetalol in the treatment of hypertensive
crisis, which differed from the result of an adult study
that showed nicardipine to be more efficacious within
30 minutes than labetalol in patients with renal dys-
function [16]. However, Thomas et al. also reported no
significant difference of efficacy between nicardipine
and labetalol in infants and small children with a
hypertensive crisis [17]. Particularly, we tried to com-
pare the hypertensive emergency with hypertensive ur-
gency in children.
Although hypertension is usually regarded as a disease
of adulthood, with a prevalence of 30 % [18], it can also
affect children and adolescents, traditionally with a
prevalence of 1 %–2 %. However, recent studies have
suggested that it has increased to over 3 %, with a much
higher prevalence of 4.5 % in children with obesity [3,
19]. Severe childhood hypertension is associated with
adulthood morbidity and mortality as a long-standing el-
evated blood pressure [14]. Ninety-day mortality rates
were reported to be 11 % in patients who were hospital-
ized and treated in emergency circumstances [20]. These
serious situations are related to acute end-organ damage
and require immediate, controlled blood pressure reduc-
tion, and close observation. Without proper treatment,
the 1-year mortality rate of hypertensive emergencies in-
creases to 90 % [10]. However, there is no formal stand-
ard of treatment for severely elevated blood pressure in
such emergency circumstances in children and adoles-
cents with renal disease. Therefore, this study serves to
demonstrate an optimal treatment option for hyperten-
sive crisis patients with renal dysfunction, with results
indicating that antihypertensive therapy should be tai-
lored to each patient.
Nicardipine hydrochloride, approved by the Food and
Drug Administration in December 1988, belongs to the
class of dihydropyridine calcium channel blockers used
to treat vascular disorders including high blood pressure,
Raynaud’s phenomenon, and chronic stable angina [13],
whereas labetalol is a mixed adrenergic antagonist that
blocks α1-receptor and nonselective β receptor with an
α:β blocking ratio of 1:7 [21]. The action mechanism of
nicardipine and its clinical effects closely resemble those
of nifedipine and the other dihydropyridines, such as
Table 5 Comparison of the effect of nicardipine and labetalol on systolic and diastolic blood pressure
Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg)
Nicardipine Labetalol P-value Nicardipine Labetalol P-value
Before treatment 158.00 ± 22.56 157.08 ± 23.86 0.756 97.54 ± 20.69 96.31 ± 14.80 0.812
30 min 141.81 ± 25.02 142.54 ± 141.81 0.651 90.09 ± 18.93 82.54 ± 16.97 0.885
1 h 134.95 ± 19.29 138.38 ± 24.88 0.498 82.27 ± 16.90 82.62 ± 19.31 0.522
2 h 129.41 ± 16.20 138.23 ± 20.81 0.105 77.32 ± 15.39 80.92 ± 18.59 0.433
4 h 122.27 ± 13.59 138.46 ± 22.20 0.087 72.23 ± 18.62 83.31 ± 18.56 0.827
5 h 124.59 ± 17.95 123.18 ± 11.98 0.167 75.77 ± 17.52 73.45 ± 16.81 0.746
Table 4 Treatment in patients with hypertensive crisis
Categories Hypertensive
emergency
(N = 31)
Hypertensive
urgency
(N = 20)
Total
(N = 51)
HD→ NCR (%) 10 (32.3) 3 (15.0) 13 (25.5)
NCR only (%) 4 (12.9) 5 (25.0) 9 (17.6)
HD→ LAB (%) 3 (9.7) 4 (20.0) 7 (13.7)
LAB only (%) 5 (16.1) 1 (5.0) 6 (11.8)
HD→ NTP (%) 0 (0.0) 3 (15.0) 3 (5.9)
NTP only (%) 0 (0.0) 0 (0.0) 0 (0.0)
Transition (%) 6 (19.4) 4 (20.0) 10 (19.6) †
LAB→ NCR (%) 4 (12.9) 2 (10.0) 6 (11.8)
NCR→ LAB (%) 0 (0.0) 0 (0.0) 0 (0.0)
NTP→ NCR (%) 3 (9.7) 0 (0.0) 3 (5.9)
NTP→ LAB (%) 0 (0.0) 1 (5.0)* 1 (2.0)
HD only (%) 3 (9.7) 0 (0.0) 3 (5.9)
HD, hydralazine; LAB, labetalol; NCR, nicardipine; NTP, nitroprusside
* 1 patient used NCR → NTP→ LAB
†Transition time: mean 50 hours
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felodipine and amlodipine; however, nicardipine is more
selective for cerebral and coronary blood vessels [13].
Moreover, nicardipine does not intrinsically reduce myo-
cardial contractility and has a longer half-life than nifedi-
pine, as labetalol causes a decrease in systemic arterial
blood pressure and systemic vascular resistance without
a substantial reduction in resting heart rate, cardiac
output, or stroke volume, apparently due to its com-
bined α- and β-adrenergic blocking activity [22, 23].
The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure declared that arterial blood pres-
sure must be decreased by no more than 10 %–25 %
during the first hour of treatment [24]. Both nicardipine
and labetalol were found to decrease SBP by 14.6 % and
11.9 % within 1 hour in our study, respectively. DBP also
decreased to 15.7 % of the initial DBP within 1 hour in
nicardipine-treated patients, whereas patients with labe-
talol treatment had 14.2 % elevated blood pressure
within 1 hour. These findings were thought to be gener-
ally caused by the fact that appropriate titration, redos-
ing, and monitoring of labetalol were not easy in a busy
emergency room, suggesting that more aggressive dosing
of labetalol might be required for blood pressure re-
sponse in patients with hypertensive emergency.
There is concern that iatrogenic effects such as
hypotension and bradycardia can occur when using
nicardipine and labetalol. Rapid blood pressure declines
in nicardipine and labetalol patients were not observed,
possibly owing to physician understanding and acknow-
ledgment. In fact, reported adverse events including
drowsiness, weakness, hyperkalemia, and drug eruption
were uncommon in our study due to the short period of
treatment. Both medications are metabolized by the
liver; therefore, patients with renal impairment may be
treated without profound complications.
We were not able to draw firm conclusions with
regard to the comparative efficacy and safety of nicardi-
pine vs. labetalol in children and adolescents with
hypertensive crisis. As the data were insufficient for
measuring long-term outcomes in patients experiencing
hypertensive crises, further research is necessary in the
near future. There is a possibility that some with hyper-
tensive emergency may not have been ultimately diag-
nosed with acute end-organ damage due to a low
SBP under 180 mmHg or a DBP under 120 mmHg.
In the treatment of such patients without hypertensive
Fig. 1 Changes in systolic (a) and diastolic (b) blood pressure by
administration of labetalol and nicardipine during 5 hours
Table 6 Comparison of 1 year follow-up outcomes of the
patients who were treated with nicardipine and labetalol
Categories Nicardipine
(N = 23)
Labetalol
(N = 18)
P-value
Primary outcomes
Mortality (%) 6 (26.0) 9 (50.0) 0.191
Survivors (%) 17 (74.0) 9 (50.0)
Secondary outcomes (in survivors)
Medication change
Taking oral medication (%) 10 (58.3) 5 (55.6) 1.000
No medication (%) 7 (41.7) 4 (44.4)
Clinical improvement
Visual symptom† (%) 0/2 (0.0) 1/2 (50.0) 1.000
Retinopathy (%) 0/2 (0.0) 1/2 (50.0) 1.000
Seizure (%) 5/5 (100.0) 2/2 (100.0) -
Cr elevation (%) 7/7 (100.0) 5/6 (83.3) 0.462
Hematuria or Proteinuria (%) 4/8 (50.0) 5/5 (100.0) 0.105
LVH, RVH, BVH on ECG (%) 1/2 (50.0) 2/3 (66.7) 1.000
Cr, serum creatinine; LVH, Left ventricular hypertrophy; RVH, right ventricular
hypertrophy; BVH, biventricular hypertrophy; ECG, electrocardiogram
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emergency, oral antihypertensive medication may have
been a reasonable option. It can be very challenging to
collect data on children and adolescents with true hyper-
tensive emergencies. Thus, the study population may not
represent the patients to whom nicardipine and labetalol
would most likely be prescribed. Additionally, ethnic dif-
ferences between Asian, African, and Caucasian popula-
tions should be taken into account.
Conclusion
In conclusion, there was no difference between nicardi-
pine and labetalol for a rapid and controlled BP decrease
of administration in children and adolescents with
hypertension and renal disease. However, these results
should be considered in the context of the patient popu-
lation and tempered with further studies to determine
whether the controlled blood pressure improvement
obtained by nicardipine or labetalol truly has any clinical
significance.
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